|
|
Article: Kyto Biopharma Inc. Confirms Definitive Isolation of the Human Vitamin B12 Receptor (TCblR).
- Article from:
- Business Wire
- Article date:
- November 21, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TCblR Novel Target for Monoclonal Antibody Cancer Therapy
TORONTO -- Kyto Biopharma Inc. (OTCBB:KBPH), ("Kyto"), a biotechnology company focused on developing monoclonal antibody based therapeutic agents for cancer treatment, announced today that for the first time it has conclusively isolated the protein and gene encoding the human Vitamin B12 receptor - TCblR for the cellular uptake of the transcobalamin-bound Vitamin B12. The over expression of TCblR in cancer cells provides the rationale for targeting the Vitamin B12 receptor in the treatment of various forms of cancer.
"The discovery of the TCblR gene and the expression of its encoded receptor ...